Mylan New Launches On Track For $1bn In 2019, But It's Not Enough
New complex generic and biosimilar launches like Wixela, Fulphila and generic Copaxone generated $250m in the first quarter, but the company's sales and earnings declined, pointing to big challenges in the base generics business.
You may also be interested in...
Europe’s ambitious new system for verifying the authenticity of prescription medicines circulating on the market is about to come into operation.
Lower prices for generic drugs in the US are continuing to drag on revenues of drug makers like Teva, Sandoz, Mylan and Endo. Industry leaders say the US market is stabilizing, but price erosion and other negative factors impacted second quarter financials across the sector. Teva is attempting a turnaround and Mylan is exploring strategic alternatives.
CEO Heather Bresch gave a soliloquy on US health care during the second quarter call, saying ‘perverse incentives’ have created a system that ‘feeds on higher prices.’